Antibody-Drug Conjugates (2nd Edition) [#909162]

Free Download Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer
English | 2025 | ISBN: 3031830040 | 483 Pages | PDF EPUB (True) | 21 MB
The field of antibody-drug conjugates (ADCs) has undergone remarkable advancements in recent years, marked by significant progress in both drug approvals and ongoing clinical development. Since the approval of the first ADC in 2010 (gemtuzumab ozogamicin, Mylotarg®), the landscape has expanded dramatically. Today, there are 11 FDA-approved ADCs, targeting a variety of cancers across multiple indications. The approved ADCs include a range of payloads, linkers, and antibodies, each optimized for a variety of specific therapeutic targets. The increasing diversity of ADCs reflects the growing potential of these innovative treatments to address a wide array of malignancies, from hematologic cancers to solid tumors.